Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.49 |
| ▸ | MAPK7 | Q13164 | 8/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL605284 | 0.88 | MAPK14 (0.49) | MAPK14MAPK7HTTSMN1; SMN2 | |
| SCHEMBL615900 | 0.86 | MAPK14 (0.56) | MAPK14MAPK7HTT | |
| SCHEMBL605344 | 0.85 | MAPK14 (0.52) | MAPK14MAPK7HTTMEN1KMT2A | |
| SCHEMBL299044 | 0.84 | MAPK14 (0.53) | MAPK14MAPK7HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL298943 | 0.84 | MAPK14 (0.46) | MAPK14MAPK7HTTSMN1; SMN2 | |
| SCHEMBL607176 | 0.84 | MAPK14 (0.48) | MAPK14MAPK7HTTSMN1; SMN2 | |
| SCHEMBL606459 | 0.83 | MAPK14 (0.52) | MAPK14MAPK7HTTSMN1; SMN2 | |
| SCHEMBL297868 | 0.83 | MAPK14 (0.46) | MAPK14MAPK7HTTSMN1; SMN2 | |
| SCHEMBL605300 | 0.82 | MAPK14 (0.47) | MAPK14MAPK7HTTALDH1A1MEN1 | |
| SCHEMBL297921 | 0.81 | HTT (0.54) | MAPK14MAPK7HTTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | MAPK14 13/4885MAPK7 4/4885HTT 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.